Biodegradable poly(sebacic acid‐co‐ricinoleic‐ester anhydride) tamoxifen citrate implants: Preparation and in vitro characterization

Abstract

The aim of this study was to prepare tamoxifen citrate loaded cylindrical polymeric implants for application at tumor sites. The implant was based on poly (sebacic acid-co-ricinoleic-ester anhydride) 70 : 30 w/w [poly(SA-RA) 70 : 30 w/w], a low-melting, biodegradable, and biocompatible polymer. Implants were prepared by a standardized melt manufacturing method. Differential scanning calorimetry and scanning electron microscopy were used for implant characterization. In vitro drug release studies were performed in phosphate-buffered saline (pH 7.4) at 37 6 28C. The drug content was estimated by high-performance liquid chromatography. The differential scanning calorimetry studies showed that the tamoxifen citrate in the implants was in the amorphous state. The cumulative percentage of drug release from 10 and 20 wt % drug-loaded poly(SA-RA) 70 : 30 w/w implants after 30 days was found to be 42.36 and 62.60%, respectively.

Preparation and in vitro characterization of paclitaxel-loaded injectable microspheres

“…[10] The screw capped bottles containing paclitaxelloaded microspheres in 25 ml of phosphate buffer saline of pH. 7.4 as release medium were fixed to stainless steel holders attached to a mechanical stirrer and the platform was immersed in water maintained at 37±2°C.…”

Preparation and in vitro characterization of poly (epsilon-caprolactone)-based tamoxifen citrate-loaded cylindrical subdermal implant for breast cancer

“…The effluent as detected UV spectrophometrically (λ =265 nm). [7] In order to account for the drug, which could be lost throughout the above procedure, the recovery efficiency of the procedure was determined by dissolving a known quantity of tamoxifen citrate in DCM and subjecting it to the same procedure as described above.…”

“…The hydrolysis of the polymer was determined by decrease in weight of implant and tamoxifen citrate content in the remaining implants. [7,8] At each time point, the formulation was examined for tamoxifen citrate content in the degraded sample by developed HPLC method.…”

Determination of tamoxifen and its main metabolites in plasma samples from breast cancer patients by micellar liquid chromatography

“…A recent paper reports the use of HPLC-MS [8], but mass spectrometry has a high cost and requires an expensive maintenance. Other authors have proposed analytical methods using liquid chromatography coupled with spectrophotometric detectors, as HPLC-DAD [11,12] (with low sensitivity) and HPLC-FLD [13][14][15][16], previous derivatization by UV-irradiation. However, due to the high number of analytes to separate, the hydroorganic mobile phases are usually programmed as gradient.…”